← Leaderboards
Detlev Boison
Legacy Emanuel Hospital And Health Center
$13,834,369
Attributed
$18,059,463
Total exposure
11
Grants
9
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.6M · FY2008–25$2M$1.5M$1M$500K$0
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$18,059,463 · 11
By mechanism
R01$14,072,329 · 7
K12$2,403,204 · 1
R21$1,583,930 · 3
Top collaborators
- Jonathan David Geiger8 shared
- Susan A Masino8 shared
- Gary Alan Brewer2 shared
- Martha C. Soto2 shared
Others in their field
Top investigators on “Brain”
- Douglas S. Hawkins · Children'S Hosp Of Philadelphia$157,315,120
- Michael W Weiner · Northern California Institute Res &Educ$149,959,854
- David A Bennett · Rush University Medical Center$148,375,056
- David Heimbrook · Leidos Biomedical Research, Inc.$145,442,397
- Walter John Curran · Thomas Jefferson University$114,442,832
- Hongkui Zeng · Allen Institute$113,960,965
Research focus
BrainPreventBaseAdenosineSeizuresEpilepsyAdenosine KinaseAffectChronicResponseRodent ModelAcuteHippocampus (Brain)Kainic AcidOverexpressionLinkMediatingDoseEpileptogenesisReceptorPurinergic P1 ReceptorsRattusMetabolicTransgenic Mice
Grant awards (45)
IRACDA at Rutgers: INSPIRE Postdoctoral Training Program$1,201,602
K12 · FY2025 · GM
Therapies for Epilepsy Prevention - Focus on Adenosine$425,721
R01 · FY2025 · NS · contact PI
IRACDA at Rutgers: INSPIRE Postdoctoral Training Program$1,201,602
K12 · FY2024 · GM
Therapies for epilepsy prevention - focus on adenosine$432,193
R01 · FY2024 · NS · contact PI
Therapies for epilepsy prevention - focus on adenosine$432,213
R01 · FY2023 · NS · contact PI
Therapies for epilepsy prevention - focus on adenosine$432,213
R01 · FY2022 · NS · contact PI
Adenosine receptor mediated therapies for SUDEP$343,438
R01 · FY2022 · NS · contact PI
Ketogenic Diet and Adenosine: Epigenetics and Antiepileptogenesis$572,913
R01 · FY2021 · NS
Adenosine receptor mediated therapies for SUDEP$343,438
R01 · FY2021 · NS · contact PI
Ketogenic Diet and Adenosine: Epigenetics and Antiepileptogenesis$546,933
R01 · FY2020 · NS
Adenosine receptor mediated therapies for SUDEP$341,250
R01 · FY2020 · NS · contact PI
Ketogenic Diet and Adenosine: Epigenetics and Antiepileptogenesis$553,731
R01 · FY2019 · NS
Adenosine receptor mediated therapies for SUDEP$341,250
R01 · FY2019 · NS · contact PI
Ketogenic Diet and Adenosine: Epigenetics and Antiepileptogenesis$580,796
R01 · FY2018 · NS
Adenosine receptor mediated therapies for SUDEP$367,500
R01 · FY2018 · NS · contact PI
Glycine augmentation therapy for the treatment of epilepsy$360,938
R01 · FY2017 · NS · contact PI
Adenosine kinase antisense gene therapy for temporal lobe epilepsy.$412,500
R21 · FY2016 · NS · contact PI
Glycine augmentation therapy for the treatment of epilepsy$360,938
R01 · FY2016 · NS · contact PI
Adenosine and schizophrenia: mechanisms and therapies$412,500
R01 · FY2015 · MH · contact PI
Adenosine kinase antisense gene therapy for temporal lobe epilepsy.$412,500
R21 · FY2015 · NS · contact PI
Glycine augmentation therapy for the treatment of epilepsy$360,938
R01 · FY2015 · NS · contact PI
Adenosine and schizophrenia: mechanisms and therapies$412,500
R01 · FY2014 · MH · contact PI
Glycine augmentation therapy for the treatment of epilepsy$360,938
R01 · FY2014 · NS · contact PI
The Role of Adenosine in Ketogenic Diet Therapy$409,207
R01 · FY2013 · NS
Adenosine and schizophrenia: mechanisms and therapies$315,058
R01 · FY2013 · MH · contact PI
Astrocyte dysfunction in epileptogenesis: the role of adenosine$293,614
R01 · FY2013 · NS · contact PI
The Role of Adenosine in Ketogenic Diet Therapy$424,047
R01 · FY2012 · NS
Adenosine and schizophrenia: mechanisms and therapies$328,185
R01 · FY2012 · MH · contact PI
Astrocyte dysfunction in epileptogenesis: the role of adenosine$304,263
R01 · FY2012 · NS · contact PI
The Role of Adenosine in Ketogenic Diet Therapy$424,007
R01 · FY2011 · NS
Adenosine and schizophrenia: mechanisms and therapies$328,185
R01 · FY2011 · MH · contact PI
Astrocyte dysfunction in epileptogenesis: the role of adenosine$304,263
R01 · FY2011 · NS · contact PI
Adenosine-releasing brain implants for epilepsy therapy$302,805
R01 · FY2011 · NS · contact PI
The Role of Adenosine in Ketogenic Diet Therapy$422,803
R01 · FY2010 · NS
Adenosine and schizophrenia: mechanisms and therapies$331,500
R01 · FY2010 · MH · contact PI
Astrocyte dysfunction in epileptogenesis: the role of adenosine$307,367
R01 · FY2010 · NS · contact PI
Adenosine-releasing brain implants for epilepsy therapy$305,894
R01 · FY2010 · NS · contact PI
Adenosine and schizophrenia: mechanisms and therapies$345,925
R01 · FY2009 · MH · contact PI
Astrocyte dysfunction in epileptogenesis: the role of adenosine$310,472
R01 · FY2009 · NS · contact PI
Adenosine-releasing brain implants for epilepsy therapy$308,984
R01 · FY2009 · NS · contact PI
Adenosine kinase as novel therapeutic target to prevent acquired epilepsy$206,981
R21 · FY2009 · NS · contact PI
Adenosine kinase as therapeutic target to induce and maintain ischemic tolerance$206,981
R21 · FY2009 · NS · contact PI
Adenosine-releasing brain implants for epilepsy therapy$323,409
R01 · FY2008 · NS · contact PI
Adenosine kinase as novel therapeutic target to prevent acquired epilepsy$172,484
R21 · FY2008 · NS · contact PI
Adenosine kinase as therapeutic target to induce and maintain ischemic tolerance$172,484
R21 · FY2008 · NS · contact PI